• 1
    A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 11101115.
  • 2
    Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344: 423438.
  • 3
    Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, McMichael JP, et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117125.
  • 4
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442450.
  • 5
    Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kreteman N, et al. Early steroid withdrawal after liver transplantation: The Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003; 9: 587595.
  • 6
    Starzl TE, Klintmalm GP, Porter KA, Iwatsuki S, Schroter GP. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 1981; 305: 266269.
  • 7
    Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998; 66: 5966.
  • 8
    Cohen AJ, Stegall MD, Rosen CG, Wiesner RH, Leung N, Kremers WK, Zein NN. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8: 916921.
  • 9
    Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741747.
  • 10
    Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931940.
  • 11
    Neuhas P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrema K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132142.
  • 12
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, et al. The safety of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 18671872.
  • 13
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbaim TM, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001; 7: 220225.
  • 14
    Bazarah SM, Peltekian KM, McAlister VC, Bittar-Suerman H, MacDonald AS. Utility of MELD and Child-Turcotte-Pugh scores and the Canadian waitlisting algorithm in predicting short-term survival after liver transplant. Clin Invest Med 2004; 27: 162167.
  • 15
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461470.
  • 16
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3134.
  • 17
    Demetrius AJ, Batts KP, Dhillon AP, Ferrell L, Fung J, Geller SA, et al. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658663.
  • 18
    Andres A, Morales JM, Farias J, Hernandez G, Gomez M, Calleja J, Moreno E, Rodicio JL. Acute renal failure after liver transplantation in patients treated with cyclosporine. Transplant Proc 1992; 24: 126167.
  • 19
    Pascual E, Gomez-Arnau J, Pensado A, de la Quintana B, Carrera A, Arribas MJ, Garcia-Guiral M, Cuermas-Mons V. Incidence and risk factors of early acute renal failure in liver transplant patients. Transplant Proc 1993; 25: 1837.
  • 20
    Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 19341939.
  • 21
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwall P, et al. Membranoproliferative glomerulonephritis associated hepatitis C virus infection. N Engl J Med 1993; 328: 505506.
  • 22
    Shapiro RJ, Steinbrecher UP, Magil A. Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. Am J Nephrol 1995; 15: 343337.
  • 23
    Axelsen RA, Crawford DH, Endre ZH, Lynch SV, Balderson GA, Strong RW, Fleming SJ. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 1995; 27: 237246.
  • 24
    Gournay J, Ferrell LD, Roberts JP, Ascher NL, Wright TL, Lake JR. Cryoglobulinemia presenting after liver transplantation. Gastroenterology 1996; 110: 265270.
  • 25
    Aldosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, Steinbruher UP, Yoshida EM. Post-liver transplantation diabetes mellitus: An association with hepatitis C. Liver Transpl 2002; 8: 356361.
  • 26
    Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 2004; 10: 349355.
  • 27
    Koch RO, Graziadei IW, Schulz F, Nachbaur K, Konigsrainer A, Margreiter R, Vogel W. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transplant Int 2004; 17: 518524.
  • 28
    Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver transplant patients with renal dysfunction. Transplantation 2003; 69: 98102.
  • 29
    Hirose R, Roberts JP, Quan D, Osario RW, Freise C, Ascher NL, Stock PG. Experience with daclizumab in liver transplantation: Renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69: 307311.
  • 30
    McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004; 10: 975985.
  • 31
    Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 10641070.
  • 32
    Cantarovich M. Renal dysfunction in liver transplantation: The problem and preventive strategies. Can J Gastroenterol 2004; 18(suppl C): 27C4-C.
  • 33
    Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 2004; 10: 301309.
  • 34
    Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004; 77: 553556.